Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
14 01 2020
Historique:
received: 21 02 2019
revised: 19 07 2019
accepted: 06 12 2019
entrez: 16 1 2020
pubmed: 16 1 2020
medline: 13 2 2021
Statut: ppublish

Résumé

Loss of p53 function contributes to the development of many cancers. While cell-autonomous consequences of p53 mutation have been studied extensively, the role of p53 in regulating the anti-tumor immune response is still poorly understood. Here, we show that loss of p53 in cancer cells modulates the tumor-immune landscape to circumvent immune destruction. Deletion of p53 promotes the recruitment and instruction of suppressive myeloid CD11b

Identifiants

pubmed: 31940491
pii: S2211-1247(19)31678-X
doi: 10.1016/j.celrep.2019.12.028
pmc: PMC6963783
pii:
doi:

Substances chimiques

Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

481-496.e6

Subventions

Organisme : Wellcome Trust
ID : FC001202
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001169
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C596/A10419
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001557
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C596/A17196
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C596/A26855
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001557
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001202
Pays : United Kingdom
Organisme : Medical Research Council
ID : FC001557
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001202
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001169
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Genome Biol. 2014;15(12):550
pubmed: 25516281
Immunity. 2007 Aug;27(2):268-80
pubmed: 17692540
Oncogene. 2014 Jun 19;33(25):3325-33
pubmed: 23873029
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):246-51
pubmed: 20018721
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Cell Cycle. 2014;13(2):220-6
pubmed: 24200967
Eur J Immunol. 2010 Mar;40(3):780-6
pubmed: 20039297
Blood. 2007 May 1;109(9):3812-9
pubmed: 17255361
FASEB J. 2011 Jul;25(7):2387-98
pubmed: 21471252
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
Cell. 2017 Nov 30;171(6):1259-1271.e11
pubmed: 29107330
Gut. 2017 Jul;66(7):1278-1285
pubmed: 27013602
Cell Mol Life Sci. 2019 Apr;76(8):1447-1458
pubmed: 30747250
J Neuroimmunol. 2003 Feb;135(1-2):29-37
pubmed: 12576221
Cancer Res. 2017 May 1;77(9):2292-2305
pubmed: 28280037
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Arthritis Rheum. 2013 Apr;65(4):949-59
pubmed: 23280308
Blood. 1998 Nov 15;92(10):3780-92
pubmed: 9808572
Nat Commun. 2013;4:2359
pubmed: 23965983
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Nat Commun. 2018 Feb 22;9(1):771
pubmed: 29472616
J Immunol. 2012 Feb 1;188(3):1064-74
pubmed: 22227569
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Nat Protoc. 2009;4(11):1670-80
pubmed: 19876027
J Immunol. 1999 Nov 15;163(10):5211-8
pubmed: 10553041
J Biol Chem. 2001 Nov 16;276(46):42957-64
pubmed: 11559700
Blood. 2011 Apr 7;117(14):3836-46
pubmed: 21270444
Nat Immunol. 2005 Jul;6(7):722-9
pubmed: 15951814
Oncogene. 1999 Dec 16;18(54):7740-7
pubmed: 10618714
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Cell Stem Cell. 2013 Jun 6;12(6):761-73
pubmed: 23665120
Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4716-21
pubmed: 20133734
Transl Oncol. 2018 Oct;11(5):1171-1187
pubmed: 30059832
Cancer Cell. 2012 Jun 12;21(6):822-35
pubmed: 22698406
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Mol Interv. 2008 Feb;8(1):22-7
pubmed: 18332481
J Immunol. 2012 Aug 15;189(4):1780-91
pubmed: 22786769
Science. 2015 Jul 31;349(6247):1261669
pubmed: 26228159
Nat Med. 2018 Feb;24(2):165-175
pubmed: 29309058
Diabetes. 2005 May;54(5):1423-8
pubmed: 15855329
Cancer Res. 2013 Mar 15;73(6):1668-75
pubmed: 23319800
Cell. 2015 Aug 27;162(5):1078-89
pubmed: 26317471
Immunity. 2017 Apr 18;46(4):577-586
pubmed: 28410988
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Methods. 2013 Aug;10(8):751-4
pubmed: 23770755
Proc Natl Acad Sci U S A. 1987 Sep;84(17):6179-83
pubmed: 2819867
J Immunol. 2013 Oct 1;191(7):3614-23
pubmed: 24006461
J Immunol. 2004 Jan 1;172(1):61-9
pubmed: 14688310
Cancer Res. 1999 Jul 1;59(13):3128-33
pubmed: 10397255
Cancer Res. 2016 Oct 15;76(20):6118-6129
pubmed: 27530326
Cell Rep. 2018 May 1;23(5):1448-1460
pubmed: 29719257
J Immunol. 2003 May 1;170(9):4457-64
pubmed: 12707321
J Exp Med. 2013 Sep 23;210(10):2057-69
pubmed: 24043758
Cancer Cell. 2012 Jun 12;21(6):836-47
pubmed: 22698407
Immunity. 2014 May 15;40(5):681-91
pubmed: 24792911
Cell. 2013 Apr 11;153(2):449-60
pubmed: 23562644
Front Oncol. 2017 Feb 22;7:24
pubmed: 28275576
Immunity. 2017 Feb 21;46(2):197-204
pubmed: 28228279
PLoS One. 2017 Jul 27;12(7):e0179726
pubmed: 28749946
Nature. 2019 Aug;572(7770):538-542
pubmed: 31367040
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Science. 1991 Jul 5;253(5015):49-53
pubmed: 1905840
Cancer Res. 2014 Apr 15;74(8):2182-92
pubmed: 24737129
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Methods Mol Biol. 2011;707:21-37
pubmed: 21287326
Nature. 2007 Feb 8;445(7128):656-60
pubmed: 17251933
Clin Cancer Res. 2009 Feb 1;15(3):778-87
pubmed: 19188147
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Cell. 2012 Apr 27;149(3):656-70
pubmed: 22541435
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Sci Rep. 2015 May 21;5:10501
pubmed: 25994622
Cell. 2017 Nov 30;171(6):1301-1315.e14
pubmed: 29195074

Auteurs

Julianna Blagih (J)

The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Fabio Zani (F)

The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Probir Chakravarty (P)

The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Marc Hennequart (M)

The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Steven Pilley (S)

The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Sebastijan Hobor (S)

The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Andreas K Hock (AK)

Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK; Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Cambridge CB4 0WG, UK.

Josephine B Walton (JB)

Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK.

Jennifer P Morton (JP)

Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK.

Eva Gronroos (E)

The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Susan Mason (S)

Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK.

Ming Yang (M)

The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Iain McNeish (I)

Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0NN, UK.

Charles Swanton (C)

The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.

Karen Blyth (K)

Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK.

Karen H Vousden (KH)

The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address: karen.vousden@crick.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH